medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2023, Number 5

<< Back Next >>

Acta Ortop Mex 2023; 37 (5)

Atypical femoral fractures due to the use of bisphosphonates. Experience of two institutions

Villegas R, Melo-Durán S, Cevallos A, Barros-Prieto E

Language: Spanish
References: 32
Page: 270-275
PDF size: 181.90 Kb.


ABSTRACT

Introduction: bisphosphonates are used for the management of postmenopausal osteoporosis with high risk of fracture, glucocorticoid-induced osteoporosis, Paget's disease and hypercalcemia; as well as an adjuvant for the management of hyperparathyroidism. Bisphosphonates have been associated with previously unknown adverse effects, including atypical femur fractures. Objective: to analyze the relationship of the history of bisphosphonate (BF) use as a risk factor for presenting atypical femur fractures (AFF). Material and methods: patients aged 40 years or older from two hospital centers seen from 2009 to 2018 for femur fracture were included. The radiographic studies of 441 records were reviewed, from which the fracture site was defined. Subtrochanteric (SF) and diaphyseal (DF) femur fractures were analyzed applying the criteria of the second report of the American Society for Bone and Mineral Research for case definition of AFF. Finally, the consumption of bisphosphonates in these groups was investigated to estimate a measure of association. Results: of the 441 clinical records, 98 (22.2%) were male and 343 (77.7%) were female with a mean age of 77.8 (40-103) years. Fifty-nine FS/FD were identified, of which 53% (31 records) were categorized as AFF. BF use was determined in 80.6% of patients with AFF and 3.57% in FS/FD. BF use was significantly associated with the presence of AFF (OR: 112, p ≤ 0.000, CI 95%: 12.6-1001). Conclusions: BF use significantly increases the risk of presenting AFF. AFF in patients who used BF occurred after a minimum consumption of 24 months.


REFERENCES

  1. Francis MD, Valent DJ. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. J Musculoskelet Neuronal Interact [Internet]. 2007; 7(1): 2-8. Available in: http://www.ncbi.nlm.nih.gov/pubmed/17396000

  2. Smith R, Russell RGG, Bishop M. Diphosphonates and Paget's disease of bone. Lancet. 1971; 297(7706): 945-7.

  3. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc [Internet]. 2008; 83(9): 1032-45. Available in: http://www.ncbi.nlm.nih.gov/pubmed/18775204

  4. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int [Internet]. 2005; 16: 468-74. Available in: http://link.springer.com/10.1007/s00198-004-1725-z

  5. Giger EV, Castagner B, Leroux JC. Biomedical applications of bisphosphonates. J Control Release. 2013; 167(2): 175-88.

  6. Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ [Internet]. 2015; 331(h3783): h3783. Available in: http://www.bmj.com/lookup/doi/10.1136/bmj.h3783

  7. Jansen JP, Bergman GJD, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum [Internet]. 2011; 40(4): 275-84.e2. Available in: http://www.ncbi.nlm.nih.gov/pubmed/20828791

  8. Brown J, Morin S, Leslie W, Papaioannou A, Cheung A. Bisphosphonates for treatment of osteoporosis. Can Fam Physician. 2014; 60: 324-33.

  9. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29(1): 1-23.

  10. Laura Asillo EG, Román Pérez FJ, Azucena Castro V, Hernández Sanz A. Fractura atípica de fémur secundaria al uso de bifosfonatos. Rev Clin Med Fam [Internet]. 2017; 10(2): 141-4. Disponible en: http://scielo.isciii.es/pdf/albacete/v10n2/1699-695X-albacete-10-02-141.pdf

  11. Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep [Internet]. 2018; 16(4): 519-29. Available in: http://www.ncbi.nlm.nih.gov/pubmed/29951870

  12. Zeng X, Zhang Y, Kwong JSW, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med [Internet]. 2015; 8(1): 2-10. Available in: http://doi.wiley.com/10.1111/jebm.12141

  13. Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg [Internet]. 2010; 126(6): 2234-42. Available in: http://www.ncbi.nlm.nih.gov/pubmed/20697313

  14. Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med [Internet]. 2010; 362(19): 1848-9. Available in: http://www.nejm.org/doi/abs/10.1056/NEJMc0910389

  15. Lo JC, Huang SY, Lee GA, Khandewal S, Provus J, Ettinger B, et al. Clinical correlates of atypical femoral fracture. Bone [Internet]. 2012; 51(1): 181-4. Available in: http://www.ncbi.nlm.nih.gov/pubmed/22414379

  16. Giusti A, Hamdy NAT, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone [Internet]. 2011; 48(5): 966-71. Available in: http://www.ncbi.nlm.nih.gov/pubmed/21195812

  17. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med [Internet]. 2011; 364(18): 1728-37. Available in: http://www.ncbi.nlm.nih.gov/pubmed/21542743

  18. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med [Internet]. 2014; 371(10): 974-6. Available in: http://www.nejm.org/doi/abs/10.1056/NEJMc1403799

  19. Thompson RN, Phillips JRA, McCauley SHJ, Elliott JRM, Moran CG. Atypical femoral fractures and bisphosphonate treatment. J Bone Joint Surg Br [Internet]. 2012; 94-B(3): 385-90. Available in: http://www.ncbi.nlm.nih.gov/pubmed/22371548

  20. Meling T, Nawab A, Harboe K, Fosse L. Atypical femoral fractures in elderly women. Bone Joint J [Internet]. 2014; 96-B(8): 1035-40. Available in: http://online.boneandjoint.org.uk/doi/10.1302/0301-620X.96B8.33306

  21. Clout A, Narayanasamy N, Harris I. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy. J Orthop Surg [Internet]. 2016; 24(1): 36-40. Available in: http://www.ncbi.nlm.nih.gov/pubmed/27122510

  22. Lee YK, Ahn S, Kim KM, Suh CS, Koo KH. Incidence rate of atypical femoral fracture after bisphosphonates treatment in Korea. J Korean Med Sci [Internet]. 2018; 33(5): e38. Available in: http://www.ncbi.nlm.nih.gov/pubmed/29349947

  23. Marcano A, Taormina D, Egol KA, Peck V, Tejwani NC. Are race and sex associated with the occurrence of atypical femoral fractures? Clin Orthop Relat Res [Internet]. 2014; 472(3): 1020-7. Available in: http://www.ncbi.nlm.nih.gov/pubmed/24166075

  24. Takakubo Y, Ohta D, Ishi M, Ito J, Oki H, Naganuma Y, et al. The incidence of atypical femoral fractures in patients with rheumatic disease: yamagata prefectural committee of atypical femoral fractures (YamaCAFe) study. Tohoku J Exp Med [Internet]. 2017; 242(4): 327-34. Available in: http://www.ncbi.nlm.nih.gov/pubmed/28883214

  25. Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med [Internet]. 2020; 383(8): 743-53. Available in: https://www.nejm.org/doi/10.1056/NEJMoa1916525

  26. Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone [Internet]. 2013; 57(2): 423-8. Available in: http://www.ncbi.nlm.nih.gov/pubmed/24063946

  27. Moncayo Bravo SD, López Gutiérrez JJ. Evaluación del manejo farmacológico de la Osteoporosis y la Osteopenia en una institución de régimen especial de Bogotá. Rev Salud Pública [Internet]. 2015; 17(4): 565-77. Disponible en: http://www.revistas.unal.edu.co/index.php/revsaludpublica/article/view/38450

  28. Instituto Nacional de Estadística y Censos. Salud, bienestar y envejecimiento [Internet]. 2009 [citado el 27 de enero de 2017]. Disponible en: http://www.ecuadorencifras.gob.ec/wp-content/descargas/Presentaciones/estadisticas_adulto_mayor.pdf

  29. Larsen MS, Schmal H. The enigma of atypical femoral fractures. EFORT Open Rev [Internet]. 2018; 3(9): 494-500. Available in: https://online.boneandjoint.org.uk/doi/abs/10.1302/2058-5241.3.170070

  30. Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis [Internet]. 2013; 5(3): 107-11. Available in: https://pubmed.ncbi.nlm.nih.gov/23858334/

  31. Hayes KN, Winter EM, Cadarette SM, Burden AM. Duration of bisphosphonate drug holidays in osteoporosis patients: a narrative review of the evidence and considerations for decision-making. J Clin Med [Internet]. 2021; 10(5): 1140. Available in: https://pubmed.ncbi.nlm.nih.gov/33803095/

  32. Marchand D, Loshak H. Duration of bisphosphonate treatment for patients with osteoporosis: a review of clinical effectiveness and guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019. Available in: https://www.ncbi.nlm.nih.gov/books/NBK551872/



EVIDENCE LEVEL

III




2020     |     www.medigraphic.com